Wang Ziwei, Li Ruiqi, Fu Weijia, Cheng Hui, Zhang Yan, Tang Gusheng, Yang Jianmin, Wang Jianmin, Ni Xiong
Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Front Immunol. 2024 Dec 24;15:1460687. doi: 10.3389/fimmu.2024.1460687. eCollection 2024.
Chronic graft-versus-host disease (cGVHD) manifests with characteristics of autoimmune disease with organs attacked by pathogenic helper T cells. Recent studies have highlighted the role of T cells in cGVHD pathogenesis. Due to limited understanding of underlying mechanisms, preventing cGVHD after allogenic hematopoietic cell transplantation (HCT) has become a major challenge.
Here, we used a representative cGVHD model with the donor C57BL/6 to recipient BALB/c combination. Post-HCT, mice were treated with IgG or anti-CD4 monoclonal antibody. The severity of cGVHD was assessed by evaluating symptoms of cGVHD and histopathology examination (H&E) of target organs. Thymus gland damage and defects of the negative selection were assessed by analyzing the CD4CD8 double-positive thymocytes, cortical thymic epithelial cells and medullary thymic epithelial cells (mTECs). Immunotolerance of CD8 T cells was assessed by detecting the expression of CD80, PD-1, GRAIL and IL-7Rα. Long-term cellular and humoral immunity associated with graft-versus-leukemia (GVL) effects were evaluated through detecting the percentage of CD4 T cells, IgG, IgM and IgA concentrations, and performing tumor challenge experiment.
Donor CD8 T cells caused thymic epithelial cells damage and impaired negative selection in recipients, leading to generation of autoreactive T cells and causing cGVHD. Anti-CD4 mAb treatment promoted immune incompetence of thymus-infiltrating CD8 T cells, facilitated recovery of CD4CD8 thymocytes and regeneration mTECs, and preserved negative-selection, but had no effects on the long-term cellular immunity and humoral immunity, resulting in preservation of GVL effect.
Our results indicate that anti-CD4 mAb therapy early post-HCT allows thymus recovery by inducing the immune tolerance of thymus infiltrated CD8 T cells, thereby alleviating thymic epithelial cells damage, preserving negative selection, and preserving long-term GVL effect at the same time.
慢性移植物抗宿主病(cGVHD)表现为自身免疫性疾病的特征,致病辅助性T细胞攻击器官。最近的研究强调了T细胞在cGVHD发病机制中的作用。由于对潜在机制的了解有限,在异基因造血细胞移植(HCT)后预防cGVHD已成为一项重大挑战。
在此,我们使用了具有代表性的cGVHD模型,供体为C57BL/6,受体为BALB/c。HCT后,用IgG或抗CD4单克隆抗体治疗小鼠。通过评估cGVHD症状和靶器官的组织病理学检查(苏木精-伊红染色)来评估cGVHD的严重程度。通过分析CD4CD8双阳性胸腺细胞、皮质胸腺上皮细胞和髓质胸腺上皮细胞(mTECs)来评估胸腺损伤和阴性选择缺陷。通过检测CD80、PD-1、GRAIL和IL-7Rα的表达来评估CD8 T细胞的免疫耐受性。通过检测CD4 T细胞百分比、IgG、IgM和IgA浓度,并进行肿瘤攻击实验,评估与移植物抗白血病(GVL)效应相关的长期细胞免疫和体液免疫。
供体CD8 T细胞导致受体胸腺上皮细胞损伤并损害阴性选择,导致自身反应性T细胞产生并引起cGVHD。抗CD4单克隆抗体治疗促进了胸腺浸润CD8 T细胞的免疫无能,促进了CD4CD8胸腺细胞的恢复和mTECs的再生,并保留了阴性选择,但对长期细胞免疫和体液免疫没有影响,从而保留了GVL效应。
我们的结果表明,HCT后早期使用抗CD4单克隆抗体治疗可通过诱导胸腺浸润CD8 T细胞的免疫耐受性来使胸腺恢复,从而减轻胸腺上皮细胞损伤,保留阴性选择,并同时保留长期GVL效应。